Matrix metallopeptidases (MMPs) 1 and 3 have been shown to contribute to the initiation, and progression of different cancers, including breast cancer (BC). In this study, we aimed to examine the relations between polymorphisms of MMP1 (rs1799750) and MMP3 (rs632478) and their circulating levels with BC. The polymorphisms were genotyped by PCR-based Restriction Fragment Length Polymorphism (RFLP) and Allele-Specific PCR (AS-PCR) among 100 patients and 100 controls. MMP1 and MMP3 serum levels were measured by enzyme-linked immunosorbent assay (ELISA). Genotype distributions of MMP1 and MMP3 genes showed significant difference between patients and controls. The distribution of 2G/2G, 1G/2G and 1G/1G genotypes for MMP1 was 74%, 2% and 24% in the patients and 38%, 2% and 60% in the controls, respectively (P = 0.0001). For MMP3 the distribution of C/C, A/C and A/A genotypes was 28%, 54% and 18% in patients and 48%, 40% and 12% in controls, respectively (P = 0.01). For MMP1, the 2G/2G genotype was linked with a higher risk of BC when compared with that of the 1G/1G genotype (OR = 4.86; 95% CI = 2.63–8.99; P = 0.0001). For MMP3, in co-dominant model, there was a higher risk of BC in A/A and A/C genotype carriers (A/A: OR = 2.57; 95% CI = 1.08–6.11; P = 0.03) (A/C: OR = 2.31 95% CI = 1.24–4.30; P = 0.008). We also showed that MMP1 and MMP3 serum level was significantly increased in BC patients compared to controls. MMP1 and MMP3 genetic variations and their circulating levels are both significantly related to BC.

基质金属肽酶（MMPs）1和3已被证明有助于包括乳腺癌（BC）在内的各种癌症的发生和发展。在这项研究中，我们旨在检查MMP1（rs1799750）和MMP3（rs632478）多态性与BC循环水平之间的关系。通过基于PCR的限制性片段长度多态性（RFLP）和等位基因特异性PCR（AS-PCR）对100例患者和100例对照进行基因型分型。MMP1和MMP3血清水平通过酶联免疫吸附测定（ELISA）测定。MMP1和MMP3基因的基因型分布显示患者与对照组之间存在显着差异。MMP1的2G / 2G，1G / 2G和1G / 1G基因型分布在患者中分别为74％，2％和24％，在对照组中分别为38％，2％和60％（P = 0.0001）。对于MMP3，C / C的分发，患者的A / C和A / A基因型分别为28％，54％和18％，对照组为48％，40％和12％（P = 0.01）。对于MMP1，与1G / 1G基因型相比，2G / 2G基因型与更高的BC风险相关（OR = 4.86； 95％CI = 2.63–8.99； P = 0.0001）。对于MMP3，在共显性模型中，A / A和A / C基因型携带者的BC风险较高（A / A：OR = 2.57； 95％CI = 1.08–6.11； P = 0.03）（A / C：OR = 2.31 95％CI = 1.24–4.30； P = 0.008）。我们还显示，与对照组相比，BC患者的MMP1和MMP3血清水平显着升高。MMP1和MMP3的遗传变异及其循环水平均与BC显着相关。与1G / 1G基因型相比，2G / 2G基因型与更高的BC风险相关（OR = 4.86； 95％CI = 2.63–8.99； P = 0.0001）。对于MMP3，在共显性模型中，A / A和A / C基因型携带者的BC风险较高（A / A：OR = 2.57； 95％CI = 1.08–6.11； P = 0.03）（A / C：OR = 2.31 95％CI = 1.24–4.30； P = 0.008）。我们还显示，与对照组相比，BC患者的MMP1和MMP3血清水平显着升高。MMP1和MMP3的遗传变异及其循环水平均与BC显着相关。与1G / 1G基因型相比，2G / 2G基因型与更高的BC风险相关（OR = 4.86； 95％CI = 2.63–8.99； P = 0.0001）。对于MMP3，在共显性模型中，A / A和A / C基因型携带者的BC风险较高（A / A：OR = 2.57； 95％CI = 1.08–6.11； P = 0.03）（A / C：OR = 2.31 95％CI = 1.24–4.30； P = 0.008）。我们还显示，与对照组相比，BC患者的MMP1和MMP3血清水平显着升高。MMP1和MMP3的遗传变异及其循环水平均与BC显着相关。我们还显示，与对照组相比，BC患者的MMP1和MMP3血清水平显着升高。MMP1和MMP3的遗传变异及其循环水平均与BC显着相关。我们还显示，与对照组相比，BC患者的MMP1和MMP3血清水平显着升高。MMP1和MMP3的遗传变异及其循环水平均与BC显着相关。